Based on its marked overexpression in multiple malignancies and its roles in promoting cell survival and proliferation, survivin is an attractive candidate for targeted therapy. Toward this end, a detailed understanding of the mechanisms regulating survivin expression in different cancer cells will be critical. We have previously shown that the RNA-binding protein (RBP) CUG-BP1 is overexpressed in esophageal cancer cells and post-transcriptionally regulates survivin in these cells. The objective of this study was to investigate the role of microRNAs (miRs) in regulating survivin expression in esophageal cancer cells. Using miR expression profiling analysis, we found that miR-214-3p is one of the most markedly downregulated miRs in two esophageal squamous cancer cell lines compared with esophageal epithelial cells. Interestingly, using miR target prediction programs, both survivin and CUG-BP1 mRNA were found to contain potential binding sites for miR-214-3p. Forced expression of miR-214-3p in esophageal cancer cells leads to a decrease in the mRNA and protein levels of both survivin and CUG-BP1. This effect is due to decreased mRNA stability of both targets. By contrast, silencing miR-214-3p in esophageal epithelial cells leads to an increase in both survivin and CUG-BP1 mRNA and protein. To determine whether the observed effect of miR-214-3p on survivin expression was direct, mediated through CUG-BP1, or both, binding studies utilizing biotin pull-down assays and heterologous luciferase reporter constructs were performed. These demonstrated that the mRNA of survivin and CUG-BP1 each contain two functional miR-214-3p-binding sites as confirmed by mutational analysis. Finally, forced expression of miR-214-3p enhances the sensitivity of esophageal cancer cells to cisplatin-induced apoptosis. This effect is abrogated with rescue expression of survivin or CUG-BP1. These findings suggest that miR-214-3p acts as a tumor suppressor and that its downregulation contributes to chemoresistance in esophageal cancer cells by targeting both survivin and CUG-BP1.
INTRODUCTION
Resistance to chemotherapy-induced apoptosis is a crucial mechanism for tumor cell survival. 1 Survivin, a member of the Inhibitor of Apoptosis Protein (IAP) family, has been shown to be overexpressed in multiple malignancies, including esophageal cancer. 2, 3 In esophageal cancer cell lines, downregulation of survivin significantly enhances the sensitivity of these cells to chemotherapy-induced apoptosis. 4 Furthermore, failure to downregulate survivin following neo-adjuvant chemoradiotherapy has been correlated with decreased survival in esophageal cancer patients. 5 Coupled with the fact that it is not expressed in most normal tissues, survivin is an enticing candidate for targeted therapy in esophageal cancer.
A thorough understanding of the mechanisms regulating survivin overexpression in esophageal cancer cells will be essential for optimizing therapeutic strategies. Post-transcriptional regulatory processes mediated by trans-acting factors such as RNAbinding proteins (RBPs), microRNAs (miRs) and long noncoding RNAs, have important roles in the control of gene expression in cancer cells. [6] [7] [8] These factors interact with multiple gene products, some of which may be involved in coordinated networks. 9 Identifying important regulators of survivin may reveal crucial nodal agents that modulate the expression of multiple targets involved in esophageal carcinogenesis.
We have previously shown that the RBP CUG-BP1 has an important role in regulating the overexpression of survivin in esophageal cancer cells by stabilizing its mRNA. 10 Although additional data on the relationship between other RBPs and survivin are scarce, several reports exist regarding the regulation of survivin by various miRs, although none exist in esophageal cancer cells. miR-34a has been shown to be downregulated in both gastric cancer and laryngeal squamous cell cancer. 11, 12 Overexpression of miR-34a in these cell lines resulted in decreased survivin expression, which led to decreased proliferation and increased apoptosis. Expression of miR-203 has been shown to be markedly attenuated in prostate, pancreas and hepatocellular cancer (HCC) cell lines. [13] [14] [15] Ectopic expression of miR-203 in these cells leads to decreased survivin expression with an associated reduction in cellular proliferation and enhancement in sensitivity to chemotherapy-induced apoptosis. Given the cell type-specific nature of the interaction between survivin and miRs, the goal of this study was to assess global miR expression in two esophageal squamous cancer cell lines compared with esophageal epithelial cells. miR target prediction models were employed to determine whether any of the most markedly downregulated miRs could interact with survivin mRNA. Functional, binding and phenotypic assays were performed to characterize this interaction.
RESULTS miR-214-3p expression is markedly decreased in esophageal cancer cell lines Global miR expression in the human esophageal epithelial (hESO) cells and the human esophageal squamous cell cancer lines TE7 and TE10 was determined by array analysis using the seventh generation miR Array (Exiqon Services, Vedbaek, Denmark). Expression levels of~2000 distinct human miRs were examined. Four hundred twenty-four miRs were found to be differentially expressed above the threshold level and formed the basis for the subsequent analysis. When the 30 miRs with the greatest magnitude of differential expression between the cancer cells and epithelial cells were analyzed, 18 were found to share similar expression patterns in both TE7 and TE10 cells. A heat map depicting the two-way hierarchical clustering analysis of these 18 miRs is depicted in Figure 1a . In Table 1 , these 18 miRs are grouped into the 11 miRs, whose expression is most markedly downregulated in the cancer cells lines (a), and the 7 miRs, whose expression is most upregulated compared with the hESO cells (b).
Based on bioinformatics analysis, mir-214-3p is predicted to bind with strong affinity to both survivin and CUG-BP1 mRNA. As seen in Table 1a , miR-214-3p is dramatically downregulated in both TE7 and TE10 cells compared with hESO cells, with a log fold change of approximately -3 in each cell line. To confirm these findings, total RNA was harvested from all three cell lines and quantitative real-time PCR (q-PCR) analysis was performed to measure miR-214-3p levels. As seen in Figure 1b , these results confirm that miR-214-3p levels are significantly decreased in TE7 and TE10 cells compared with hESO cells.
Modulating miR-214-3p levels leads to alterations in both survivin and CUG-BP1 protein expression Because basal levels of miR-214-3p are low in TE7 and TE10 cells, transfection of pre-miR-214-3p into these cells was performed in order to assess the effects on survivin and CUG-BP1 protein expression. In reciprocal experiments, anti-miR-214-3p was employed to reduce miR-214-3p levels in hESO cells. As shown in Figure 2A , transfection efficiency of pre-miR-214-3p was robust in both TE7 and TE10 cells (a). Similarly, transfection of antimiR-214-3p was very effective in reducing miR-214-3p levels in hESO cells (b). Following successful transfection of pre-miR-214-3p, both survivin and CUG-BP1 protein levels are markedly decreased in TE7 and TE10 cells ( Figure 2B a,b) . Of note, there was no effect on protein levels of the RBP HuR, which has also been shown to regulate survivin expression. 16 Conversely, both survivin and CUG-BP1 protein levels were increased in hESO cells following transfection of anti-miR-214-3p ( Figure 2B c) . There was no change in HuR expression following silencing of miR-214-3p in hESO cells. miR-214-3p reduces both survivin and CUG-BP1 mRNA stability To further investigate the mechanism by which miR-214-3p affects survivin and CUG-BP1 protein expression, levels of survivin and CUG-BP1 mRNA were assessed following overexpression of premiR-214-3p in TE7 and TE10 cells, as well as following transfection of anti-miR-214-3p in hESO cells. As seen in Figure 3A , transfection of pre-miR-214-3p was associated with a decrease in both survivin and CUG-BP1 mRNA levels in both TE7 and TE10 cells. In hESO cells, reduction of miR-214-3p expression led to an increase in both survivin and CUG-BP1 mRNA levels ( Figure 3B ). Figure 3C depicts stability of both survivin and CUG-BP1 mRNA following transfection of pre-miR-214-3p in TE7 cells.
In these experiments, 24 h following transfection, cells are exposed to 0.2 μM of Actinomycin D to prevent further transcription. Total cellular RNA is harvested at specified time points and levels of target mRNA are measured by q-PCR. As seen in these curves, both survivin and CUG-BP1 mRNAs are destabilized following pre-miR-214-3p transfection. The stability curves in Figure 3D demonstrate enhanced stability of both survivin and CUG-BP1 mRNA following silencing of miR-214-3p in hESO cells. miR-214-3p binds to both survivin and CUG-BP1 mRNA As it was not clear whether the observed effect of miR-214-3p on survivin mRNA and protein expression resulted from a direct interaction with survivin mRNA, indirectly through an interaction with CUG-BP1 mRNA, or both, we next sought to determine whether miR-214-3p bound to both survivin and CUG-BP1 mRNA. As seen in Figure 4a , there are three predicted miR-214-3p-binding sites in the 3' untranslated region (UTR) of survivin mRNA. For CUG-BP1 mRNA, there are five predicted binding sites for miR-214-3p. Two are located in the coding region (CR) and three are found in the 3' UTR. As a first step in the binding analysis, following transfection of biotin-labeled miR-214-3p into TE7 cells, cell lysates were exposed to avidin-coated beads. RNA was harvested from the pull-down material and amplified with survivin, CUG-BP1 and HuR probes by q-PCR. A biotin-labeled scrambled miR served as a control in these experiments. The levels of survivin mRNA and CUG-BP1 mRNA were markedly elevated in the pull-down material isolated from TE7 cells following transfection with biotin-labeled miR-214-3p compared with control ( Figure 4b ). There was no difference in the levels of HuR mRNA.
To determine which potential binding sites in survivin mRNA were being utilized for binding with miR-214-3p, five fragments were PCR amplified and separately subcloned into luciferase reporter vectors (Figure 5a ). One fragment (FL 3'UTR) contained the entire full-length 3'UTR. Fragment 1 encompassed the CR, which does not contain a binding site, whereas the remaining three fragments of the 3'UTR each contained an individual binding site. Following co-transfection with pre-miR-214-3p or control miR, there was an~50% reduction in luciferase activity with FL 3' UTR. Co-transfection with either Fragment 2 or 4 with pre-miR-214-3p resulted in an~25% decrease in luciferase activity. There was no decrement in luciferase activity following transfection with either Figure 5d ), no decrement in luciferase activity was observed following cotransfection with either mutated fragment and pre-miR-214-3p. Finally, mutating both binding sites in FL 3'UTR resulted in complete abrogation of the 50% decrement in luciferase activity seen with the wild-type full-length construct (Figure 5e) .
A similar set of experiments was performed to analyze the relative contributions of the five predicted binding sites for miR-214-3p in CUG-BP1 mRNA. Five fragments of CUG-BP1 mRNA, each containing a unique potential binding site, were PCR amplified (Figure 6a ). Fragments 1 and 2 contained binding sites located within the CR, whereas Fragments 3-5 contained binding sites located in the 3' UTR. Each fragment was then separately subcloned into a luciferase reporter vector. Following cotransfection of pre-miR-214-3p or control miR with each construct, luciferase activity was measured. As seen in Figure 6b luciferase activity was decreased by~50% following transfection with the construct containing the binding site in Fragment 1 in the CR and by~40% following transfection with the construct containing the binding site in Fragment 4 in the 3' UTR. There were no significant changes in luciferase activity following transfection with the constructs containing the other three potential binding sites. Finally, site-directed mutagenesis was performed to alter three bases in the seed sequence-binding region of the predicted miR-214-3p-binding sites in Fragments 1 and 4. These mutated fragments were then cloned into luciferase reporter vectors. As seen in Figures 6c and d, co-transfection of the mutated constructs and pre-miR-214-3p abrogated the decrement in luciferase activity seen with the wild-type constructs.
Overexpression of miR-214-3p enhances susceptibility of TE7 cells to cisplatin-induced apoptosis Based on our previous findings that silencing either survivin or CUG-BP1 enhanced the sensitivity of TE7 cells to chemotherapy-induced apoptosis, we predicted similar results following forced expression of miR-214-3p in these cells. In the time-course experiment depicted in Figure 7A , TE7 cells were transfected with pre-miR-214-3p or control miR for 48 h. At that time, cells were exposed to 15 μM cisplatin and cell lysates harvested at various time points. Western blot analysis of lysates harvested 24 h following cisplatin exposure revealed a marked increase in caspase-3 protein levels in cells transfected with pre-miR-214-3p compared with control. To determine whether the observed enhancement in apoptosis following overexpression of miR-214-3p was due to its reduction in survivin and/or CUG-BP1 levels, rescue experiments were performed. As seen in Figure 7B , overexpression of either survivin or CUG-BP1 following transfection of miR-214-3p restores expression of these proteins. Following restoration of either survivin or CUG-BP1 expression, TE7 cells exposed to cisplatin following transfection with pre-miR-214-3p no longer demonstrate release of caspase-3 ( Figure 7C ).
To ensure that the observed caspase-3 seen following miR-214-3p overexpression was functional, a caspase-3 ELISA assay was performed under the same conditions. This revealed a twofold increase in caspse-3 enzyme activity following 24 h of exposure to cisplatin in TE7 cells transfected with pre-miR-214-3p relative to control ( Figure 7D ). To further confirm this increased sensitivity to cisplatin-induced apoptosis, TE7 cells underwent flow cytometry analysis for Annexin-V expression. Treatment with pre-miR-214-3p alone or control miR plus cisplatin resulted in~5-10% of cells staining positive for Annexin-V expression, whereas over 50% of TE7 cells transfected with pre-miR-214-3p and exposed to cisplatin stained positive for Annexin-5 ( Figures 7E and F) . 
DISCUSSION
Our findings indicate that miR-214-3p is markedly downregulated in esophageal squamous cancer cell lines compared with esophageal epithelial cells. We also demonstrate that miR-214-3p regulates survivin expression in these esophageal cancer cells, by both a direct interaction with survivin mRNA, as well as indirectly through an interaction with CUG-BP1 mRNA. Forced expression of miR-214-3p in esophageal cancer cells leads to a decrease in both mRNA and protein levels of survivin and CUG-BP1, associated with decreased mRNA stability of both targets. Finally, overexpression of miR-214-3p results in markedly enhanced sensitivity of esophageal cancer cells to cisplatin, which is abrogated following rescue expression of either survivin or CUG-BP1.
The analysis of global miR expression in both TE7 and TE10 cells compared with hESO cells is in agreement with a study from Matsushima and colleagues who compared miR expression between the esophageal squamous cancer cell lines TE10 and OE-21 and the immortalized esophageal epithelial line Het-1A. 17 All five of the miRs 200c, 203, 205, 429) found to be most upregulated in their study were also upregulated by at least 2log-fold in both cancer cell lines in our analysis. Seven of the nine miRs (miRs-10a, 99a, 100-5p, 125b, 146b, 376a, 379) found to be most downregulated in the cancer cell lines were also downregulated by 1 to 2log-fold in the TE7 and TE10 cell lines used in our study. The relative expression of miR-214-3p was not detailed in their report. However, in a study comparing miR expression in 40 esophageal squamous cell cancer specimens and matched normal tissues, miR-214-3p was found to be significantly downregulated in 77.5% of samples. 18 The data presented here not only demonstrate a new role for miR-214-3p as an important post-transcriptional regulator of survivin in esophageal squamous cancer cells, but also, by describing its interaction with CUG-BP1, enhance the understanding of the complex regulatory relationships that exist between miRs and RBPs. 19 In the only other study describing post-transcriptional regulation of CUG-BP1, miR-503 was shown to negatively influence the translational efficiency of CUG-BP1 mRNA in intestinal epithelial cells. 20 In that report, similar to our results with miR-214-3p, altering expression of miR-503 profoundly affected the anti-apoptotic effect promoted by CUG-BP1. Silencing miR-503 resulted in increased levels of CUG-BP1, which protected cells from TNFα-induced apoptosis. Intriguingly, the upregulated targets of CUG-BP1 responsible for this phenomenon, c-IAP1 and c-IAP2, are members of the same IAP family as survivin. Furthermore, simultaneous silencing of miR-503 and CUG-BP1 abolished this increase in c-IAP1 and c-IAP2 levels, providing additional evidence that CUG-BP1 enhances the expression of these anti-apoptotic proteins.
Our findings indicate that the pro-apoptotic effect observed following forced expression of miR-214-3p, is related at least in part, to the reduction in survivin expression. It is certainly possible, however, that additional targets of both miR-214-3p and CUG-BP1 may also be reduced. Alterations in levels of both miR-214-3p and CUG-BP1 have been shown to affect sensitivity to chemotherapyinduced apoptosis in cancer cells, although their expression and targets vary considerably across different malignancies. In ovarian cancer cells, where miR-214-3p is overexpressed compared with normal tissues, miR-214-3p was shown to downregulate phosphatase tensin homologue. 21 Phosphatase tensin homologue downregulation led to the activation of the Akt pathway, thereby promoting cell survival and resistance to cisplatin. Similarly, in nasopharyngeal cancer, the upregulation of miR-214-3p led to decreased levels of the pro-apoptotic protein Bim. 22 Conversely, miR-214-3p has been shown to be downregulated relative to normal cells in HCC and cervical cancer. In each case, miR-214-3p was found to target an anti-apoptotic gene; XBP-1 in HCC and Bcl2l2 in cervical cancer, such that the loss of miR-214-3p in these cells resulted in the increased expression of its anti-apoptotic targets. 23, 24 In addition, forced expression of miR-214-3p in the esophageal squamous cancer cell line Eca109 inhibited expression of the enhancer of zeste homolog 2. 18 Of note, enhancer of zeste homolog 2 was also found to be a target of miR-214-3p in HCC. 25 In both reports, overexpression of miR-214-3p led to decreased proliferation and invasion capacity of the transfected cancer cells.
In addition to our previous description of its role in regulating survivin expression in esophageal cancer cells, other evidence supports an important role for CUG-BP1 in promoting an antiapoptotic phenotype in cancer cells. CUG-BP1 has been shown to be overexpressed in both oral squamous cancer cell lines and human tumors. 26 In these cells, CUG-BP1 bound to the 3'UTRs of the mRNAs encoding the pro-apoptotic proteins BAD and BAX, and facilitated their degradation. Silencing CUG-BP1, therefore, resulted in increased levels of BAD and BAX and enhanced sensitivity to chemotherapy-induced apoptosis. Gareau and colleagues described the ability of CUG-BP1 to mediate resistance to the proteasome inhibitor bortezomid in HeLa cells by stabilizing p21 mRNA. 27 Together with our findings, these data regarding targets of miR-214-3p and CUG-BP1 in cancer cells raise the intriguing possibility that miR-214-3p and/or CUG-BP1 could serve as important regulators of multiple anti-apoptotic effectors in esophageal cancer cells. This suggests a model in which loss of these post-transcriptional regulators could be important events in esophageal carcinogenesis. 
MATERIALS AND METHODS

Cell culture and reagents
The human esophageal squamous cancer cell lines TE7 and TE10 are kind gifts from Dr Nishihira (Tohoku University, Sendai Japan). These cell lines were cultured in RPMI media (Mediatech Inc, Herndon, VA, USA) supplemented with 10% heat-inactivated fetal bovine serum. hESO is a spontaneously immortalized esophageal epithelial cell line derived from esophageal specimens harvested at the time of donor lung procurement. These cells were cultured in BEBM media (Lonza Corp, Walkersville, MD, USA) supplemented with 20% heat-inactivated fetal bovine serum and the BEGM bullet kit. All cells were maintained in a 37°C incubator with 5% CO 2 humidified air.
Transfection
Cells were seeded in 6-cm plates at a density of 0.5-1 × 10 6 , a day before transfection. For miR transfections, pre-miR-214-3p (12 nM), anti-miR-214-3p (25 nM) or control miR (Ambion, Austin, TX, USA) was diluted in 500 μl Opti-MEM I (Invitrogen, Carlsbad, CA, USA) containing 5 μl Lipofectamine RNAiMAX (Invitrogen). After 15 min incubation at room temperature (RT), the complex was added to the cells in a final volume of 5 ml of fresh medium. To transiently overexpress CUG-BP1 and survivin, TE7 cells were transfected with 2 μg of pCMV6-XL5 plasmid containing CUG-BP1 or survivin cDNA (OriGene, Rockville, MD, USA) diluted in 500 μl Opti-MEM I containing 5 μl Lipofectamine 2000 (Invitrogen).
Global miR expression profiling hESO, TE7 and TE10 cells (two replicates each) were seeded in 6-cm plates at passage 5. Total RNA was isolated using miRNeasy Mini Kit (Qiagen, Valencia, CA, USA) according to the manufacturer's manual. All the experiments for miR array were conducted at Exiqon Services. Briefly, RNA quality was verified by an Agilent 2100 Bioanalyzer profile (Agilent Technologies, Santa Clara, CA, USA). Total RNA (750 ng) of each sample and common reference was labeled with Hy3 and Hy5 fluorescent label using the miRCURY LNA microRNA HiPower labeling kit (Exiqon). RNA samples were mixed pairwise and hybridized to the miRCURY LNA microRNA array seventh generation, which contains capture probes targeting all miRs for human listed in miRBASE 18.0. Hybridization was performed using a Tecan HA4800 hybridization station (Tecan, Männedorf, Switzerland). Slides were then scanned using Agilent G2565BA Microarray Scanner system and image analysis was carried out using ImaGene9 microRNA Array analysis software. The quantified signals were background corrected (Normexp with offset value10) and normalized using the global Lowess (Locally Weighted Scatterplot Smoothing) regression algorithm. 28 For each comparison the fold change is listed as log2 transformed values. The fold change is calculated as 2^logFC. All calculations have been done with R/Bioconductor software using mainly the limma package. 29 All microarray data are deposited in the Gene Expression Omnibus (GEO data base accession No: GSE67016).
Reverse transcription-PCR (RT-PCR) and q-PCR analyses
For all the reverse transcription-PCR and q-PCR experiments, total RNA was isolated from each sample using miRNeasy Mini Kit (Qiagen) according to the manufacturer's manual and quantitated using NanoDrop1000 spectrometry (Thermo Scientific, Wilmington, DE, USA). Equal amounts (1 μg) of total RNA were reverse transcribed using Oligo dt primer and AMV reverse transcriptase (Reverse Transcription System, Promega, Madison, WI, USA). Ten nanograms of total RNA per 15 μl reaction were reverse transcribed using TaqMan miR reverse transcription kit with specific miR primers (Applied Biosystems, Foster City, CA, USA). Q-PCR was performed in miR-214-3p targets survivin and CUG-BP1 P Phatak et al triplicate with specific (Survivin, CUG-BP1, HuR, miR-214-3p, U6 and glyceraldehyde 3-phosphate dehydrogenase) TaqMan primers and probes (Applied Biosystems). Two microliters of cDNA were used in total 20 μl volume per reaction. Reactions were run on a STEP-ONE Plus Real-Time PCR System (Applied Biosystems) and cycling conditions were as follows: 2 min at 50°C, 10 min at 95°C, followed by 40 cycles of 15 s at 95°C and 1 min at 60°C. The threshold limit was set so that it intersected all the samples during the log-liner phase of amplification. The levels of glyceraldehyde 3-phosphate dehydrogenase were used to normalize levels of survivin, CUG-BP1 and HuR in q-PCR samples. For miR experiments, normalization was accomplished using small nuclear RNA U6.
Immunoblotting
Thirty micrograms of protein from whole-cell lysates were resolved on 10% SDS-polyacrylamide gel electrophoresis gels (Bio-Rad Laboratories, Hercules, CA, USA) and transferred onto poly(vinylidene fluoride) membranes (GE Healthcare, Piscataway, NJ, USA). After transfer, membranes were blocked in 5% nonfat milk in tris buffer saline and tween 20 and membranes were incubated with specific antibodies (overnight at 4°C) followed by horseradish peroxidase-conjugated anti-mouse or anti-rabbit (Santa Cruz Biotechnology, Dallas, TX, USA) immunoglobulin for 1 h at RT. Signal was detected by Chemiluminescence Reagent (PerkinElmer, Waltham, MA, USA) and visualized by autoradiography. Anti-human survivin antibody was purchased from R&D Systems (Minneapolis, MN, USA). Anti-CUG-BP1, anti-HuR and anti-glyceraldehyde 3-phosphate dehydrogenase antibodies were purchased from Santa Cruz Biotechnology. All primary antibodies were used at a dilution of 1:2000 and all secondary antibodies were used at a dilution of 1:4000. Signal intensity was quantified using Image Lab quantification software (Bio-Rad, Hercules, CA, USA).
Bioinformatics
Two software programs, RegRNA 2.0 (regrna.mbc.nctu.edu.tw) and Weizmann Institute of Science (http://genie.weizmann.ac.il/index.html), were used to predict the potential target genes of miR-214-3p. mRNA stability mRNA stability assays were performed as previously reported. 30 Twenty-four hours following transfection as described above, medium containing Actinomycin D (Sigma-Aldrich, St Louis, MO, USA) at a final concentration of 0.2 μM was added for specified time points. Total RNA was isolated from each sample and quantitative reverse transcription-PCR was performed in triplicate as described above.
Biotin-labeled pull-down assays Biotinylated miR-214-3p (Dharmacon, Lafayette, CO, USA) pull-down assay with target mRNAs was performed as described earlier. 31, 32 Briefly, 1 × 10 6 TE7 cells were seeded in 10-cm plate in duplicate a day before transfection. Next day, control miR or 3' biotin-labeled miR-214-3p (5′-ACAGC AGGCACAGACAGGCAGU-3′Bi) was transfected at a final concentration of 50 nM. After 48 h, whole-cell lysates were harvested. Simultaneously, Streptavidin-Dyna beads (Dyna beads M-280 Streptavidin, #11205D, Invitrogen, 50 μl each sample) were coated with 10 μl per sample yeast tRNA (stock 10 mg/ml, Ambion) and incubated with rotation at 4°C for 2 h. Then beads were washed with 500 μl lysis buffer and resuspended in 50 μl lysis buffer. Sample lysates were mixed with pre-coated beads (50 μl per sample) and incubated overnight at 4°C on a rotator. Beads were then pellet down next day to remove unbound materials at 4°C for 1 min, 5 K r.p.m. and washed five times with 500 μl ice-cold lysis buffer. To isolate the RNA, 750 μl of TRIzol (Invitrogen) and 250 μl nuclease-free water was added to both input and pull-down samples. Tubes were mixed well and kept in − 20°C for 2 h. RNA was then precipitated using standard chloroform-isopropanol method and then subjected to q-PCR as explained above.
Apoptosis studies For caspase activation assays, cells were exposed to cisplatin following transfection with pre-miR-214-3p for 24 h and cleaved caspase was measured by western blot analysis using rabbit anti-caspase-3 (Cell Signaling, Danvers, MA, USA). Caspase enzyme activity was measured in triplicate for each experiment, using instant ELISA kit (eBioscience Inc., San Diego, CA, USA), following the manufacturer's instructions.
Luciferase reporter assay
Luciferase reporter constructs were prepared as previously described. 33 For survivin (Variant 1 NM_001168.2), individual luciferase reporter constructs were generated that contained either the CR, full-length 3' UTR, or one of three separate 3'UTR fragments. For CUG-BP1 (Variant 5 NM_ 001172640), the constructs contained either one of two CR fragments or one of three separate 3' UTR fragments. The inserts were amplified by PCR and individual fragments were subcloned into a NheI and SalI or SacI and Xba1 (New England Bio Labs, Ipswich, MA, USA) digested pmirGLO DualLuciferase miRNA target expression vector (Promega). The constructs containing mutations at the seed sequence-binding region of potential binding sites were generated using site-directed mutagenesis kit (Agilent Technologies). All primer sequences used to create these constructs are listed in Tables 2 and 3 . Restriction enzyme digestion and DNA sequencing confirmed the orientation and sequence of the constructs. For luciferase activity assay, 1 × 10 5 TE7 cells/well were plated onto 12-well cell culture plates and co-transfected as described above with luciferase reporter constructs (10 ng) and pre-miR-214-3p (50 nM) for 36 h. Luciferase activity was measured using Dual-Luciferase Reporter Assay kit (Promega), as per the manufacturer's protocol. Levels of firefly luciferase activity were normalized to Renilla luciferase activity.
Statistical analysis
Results are expressed as the means ± s.d. from three independent experiments with minimum three replicates for each set of experiment. Data derived from multiple determinations were subjected to two-tailed Student's t-test and P valueso0.05 were considered statistically significant. miR-214-3p targets survivin and CUG-BP1 P Phatak et al
